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dations is cost-effectiveness information. Currently in Poland there is no specific 
formal threshold for orphan designations, there is only a general cost-effectiveness 
threshold that equals 3 x GDP per capita for ICUR/QALY (for CUA) or ICER/LYG (for 
CEA), which in 2014 is approximately € 26 800. We extracted data on orphan drugs 
from our database of medical technologies assessments from 2009 to March 2014. 
Data on the cost-effectiveness (QALY / LYG) were put together with the decision of 
reimbursement. On the basis of these data the threshold of cost effectiveness in 
Poland for orphan designations was determined and summarized with the cost-
effectiveness thresholds current for a given time interval. Determination of the 
threshold of cost effectiveness for orphan designations, that would be different 
(higher) than the generally accepted cost-effectiveness threshold (due to high price 
of orphan drugs to provide value for money is unlikely), is particularly important 
from an ethical point of view, because of substantial therapeutic meaning of these 
drugs and/or absence of other treatment options of proven benefit for the disease.
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Objectives: The slow reaction of French authorities to the “Mediator saga” 
in France led to investigations that questioned the way conflicts of interest are 
reported. This policy research reviewed the Loi Bertrand, known as French Sunshine 
Act, and reported case law from the French Council of State (COS) related to conflict 
of interest in HTA recommendations. MethOds: Literature review and analysis of 
recent laws and decrees were conducted to understand French policy in the field 
of conflict of interest. A review of COS’ decisions related to conflicts of interest 
among members of HAS commissions was performed. Results: France imple-
mented the Loi Bertrand in May 2013 with the aim of specifying the scope of disclo-
sure obligations. It affects most of the agreements concluded between health care 
professionals and companies and covers a vast range of health products. Six cases 
examined by the COS were analyzed, most of them related to removal of products 
from refundable list. Four cases led to suspension or invalidation of decisions based 
on HAS recommendations due to conflicts of interest. In the two other cases the 
HAS provided the declarations of interest when required by the COS and the COS 
considered the conflicts of interest as irrelevant for the decision. It appears that 
the COS based its decisions on two main criteria: the acknowledgement of negative 
conflict of interest (link with competitors) and the unavailability of declarations 
of conflict of interest, which have to be provided by latest when required by legal 
authorities. cOnclusiOns: The strengthening of the regulation on declarations 
of interest might lead to more transparency but also more cases ruled by the COS.
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Objectives: Vaccination not only results in direct protection to those being vac-
cinated, it also has the potential of inducing indirect protection among unvaccinated 
individuals (= herd protection or positive externality). However, negative unintended 
consequences or externalities may also result from vaccination programmes (e.g. 
rebound effects). It is our purpose to present how and when these positive and 
negative externalities can be observed and measured. MethOds: We first identify 
under what conditions herd protection is most likely to occur. We then explore how 
negative rebound effects can also be manifested. Detailed illustrations of both posi-
tive and negative effects are presented for different infections in relation to mass 
vaccination programmes. Lastly, we discuss methods for observing and measuring 
these externalities. Results: Optimal herd protection is likely to be observed when 
the vaccine has a high quality-induced immunity, substantial effect on the force of 
infection, and appropriate vaccine coverage and distribution. Example: HPV vac-
cination of 12-16 year old girls resulted in a 50% decrease of anogenital warts in 
15-19 year aged adolescents in Denmark observed over a 4-year period. Rebound 
effects may potentially occur due to vaccine-related age shifting, decreased natural 
immunity, serotype replacement, low-medium coverage and non-homogeneous 
vaccine distribution. Example: increased herpes zoster incidence in elderly post-
varicella vaccine introduction. Those externalities can be captured through observa-
tional studies using real-life data, or may be estimated using dynamic transmission 
modelling techniques. cOnclusiOns: Limitations are inherent in those studies 
and involve substantial ambiguity in the process of observing and quantifying the 
indirect effects, making accurate evaluation troublesome. However the nature of 
these outcomes could be critical for achieving good economic value when deci-
sion- makers are evaluating a novel vaccine for introduction into a particular region 
or people group. More investigation is needed to identify and develop successful 
assessment methodologies for precisely analysing these outcomes.
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Randomised controlled trials (RCTs) have historically been considered the primary 
source of evidence to support market access and reimbursement. However, real-world 
data (RWD) are increasingly being considered by industry and payers. The objectives 
of this research were to review the current perception of RWD across Europe and to 
assess how RWD can support market access and reimbursement. A review of the 
literature, guidelines from European health technology assessment (HTA) agencies 
national immunization programme. Some lower and middle income countries with 
fairly strong alignment scores for recently established NITAGs have basic immunisa-
tion programmes. This study also found that NITAGs are usually developed following 
a stepwise maturing process. cOnclusiOns: Our detailed analysis of data from 35 
countries suggests that, with the right support, all countries – regardless of their GDP/
capita, health expenditures and geographical location – have the potential to establish 
highly performing NITAGs that are well-aligned with international recommendations. 
Well-aligned NITAGs are generally instrumental for having strong immunisation pro-
grammes. Through awareness of its position in this maturation process, a NITAG can 
focus on the appropriate next step for development and strengthening.
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Objective: Advances in early cancer diagnosis and treatment are enabling patients 
to live longer with more fulfilling lives. The value assessment in such cases is 
compelling. Many novel treatments for late-stage cancer also extend life, though 
prognosis may still be poor. The valuation of such life-extending treatments can 
be significantly reduced by health care costs associated with managing patients 
for longer. This study highlights discontinuities between HTA for treatments that 
extend patients’ lives and the NHS’s objective to improve cancer patients’ sur-
vival rates. MethOds And Results: Economic comparison of two treatments 
with an equivalent QALY gain, one that extends life while the other enhances the 
quality of life, indicates that to achieve a common cost per QALY outcome the 
life-extending treatment must be valued lower than the life-enhancing therapy. 
This anomaly arises primarily because the value assessment for life-extending 
treatments includes NHS costs of patient management during their extended life 
in addition to the new treatment costs. For long-term chronic conditions these 
additional costs may be easily offset; however, for severe, debilitating, or terminal 
diseases the impact can be significant. Furthermore, for new treatments added in 
combination to standard care, the greater the cost of existing care the lower the 
value that may be placed on the new life-extending treatment, to the point that 
new therapies may be deemed uneconomical even if available at no cost to the NHS. 
These findings challenge the equitable use of ICERs for HTA including the account-
ing for health services costs during the extended lifetime of a patient achieved with 
a new treatment. cOnclusiOn: Value-based metrics used to appraise new treat-
ments can inadvertently discriminate against life-extending therapies. Use of the 
ICER in HTA can result in inconsistency with health service objectives e.g. the UK 
Government’s goal to improve 1-year and 5-year survival rates for cancer patients.
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cOntext: Theoretical and empirical evidence has demonstrated that health care 
is a major driver of economic growth. The European economic crisis has resulted in 
health care budget cuts conferring consequences for health systems. Preventative 
programmes, and particularly vaccination, are most vulnerable to short-term cuts 
because their benefits are not always immediately identifiable. Although its huge 
public health benefits are recognised, only a minor fraction of the health care budget 
is allocated to vaccination. It has been suggested that cost-effectiveness analy-
ses, as used in HTA as part of recommendations and reimbursement decisions, 
may render a too narrow perspective of the overall economic benefits of vaccina-
tion. Objectives: The aim of this project is to demonstrate that, in addition to 
contributing to health care system sustainability, vaccines have importance for 
wider economic planning. A seven-chapter report was developed to highlight the 
full economic value of vaccination from different perspectives: macro-economic, 
health care system, society… Each chapter is illustrated with existing evidence 
retrieved from peer-reviewed publications. The objective of this report is threefold: 
1) to demonstrate the full economic value of vaccination with real life examples; 2) 
to inform policy-makers on how immunisation contributes to health care systems 
sustainability and efficiency; 3) to launch a call for action for the consideration of 
the full economic value of vaccination. discussiOn: Immunisation programmes 
require adequate value recognition to ensure quick population access and wide 
acceptability. Policy-makers should acknowledge that prevention through vaccina-
tion involves low levels of investment relative to the substantial incremental ben-
efits it procures. As with other preventative interventions, it is difficult to evaluate 
the true economic value of vaccines given a number of benefits are intangible and 
thereby difficult to quantify in pure monetary terms. Taking into account the full 
economic benefits of vaccination will allow understanding why prevention is the 
one of the best ways to find efficiency gains.
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The aim of this study was to identify the cost-effectiveness threshold for an orphan 
designations in Poland. According to criteria specified by the European Medicines 
Agency (EMA) a medicine must meet a strict criteria to qualify for orphan designa-
tion, such as: treatment, prevention or diagnosis of a disease that is life-threatening 
or chronically debilitating; disease prevalence level in the European Union (EU) of 
no more than 5 cases in 10,000 patients is necessary; no satisfactory method of 
disease diagnosis, prevention, treatment or if such method exists, the drug must 
deliver significant benefits to patients. In Poland, orphan drugs undergo full phar-
macoeconomic evaluations and coverage decision processes similar to any other 
innovative medicines. One of the important element of reimbursement recommen-
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The National Institute for Health and Care Excellence (NICE) in England and Wales 
is currently piloting a process whereby decision problem meetings are held sev-
eral months before starting a technology appraisal, rather than approximately 10 
weeks after formal invitation for the manufacturer to submit evidence, per current 
protocol. In general, the purpose and outcomes of the meeting, involving the NICE 
team and representatives from the evidence research group (ERG), do not change 
other than happening earlier. However, the meeting does allow manufacturers and 
sponsors to signal potential regulatory developments during the appraisal, ahead 
of the submission, to indicate potential inclusion and handling of patient access 
scheme proposals. For the meeting, an outline is required to demonstrate how the 
manufacturer/sponsor intends to approach the decision problem. This outline is 
to include, but is not limited to: evidence sources to be used; evidence likely to 
become available during the appraisal and how this might be managed; the planned 
approach to disease and economic modelling; potential challenges in interpreting 
the evidence; proposed approach to handling of uncertainty. If adopted, there are 
several implications of this new process for manufacturers/sponsors: market access 
strategy will need to be considered earlier than currently, with implications for data 
availability and analyses, value story development, positioning and indications, 
etc; cost-effectiveness models and their base cases will need earlier definition and 
completion; intentions regarding patient access schemes must be made before sub-
mission; ERGs may be reviewing limited published evidence in fast-moving therapy 
areas;, manufacturer market access groups will require more information from 
clinical, regulatory, medical affairs, modellers, epidemiologists much sooner that 
they currently do. Therefore, this seemingly simple change of meeting date rela-
tive to time of submission has important implications for manufacturers beyond 
their market access teams that require careful consideration in terms of planning 
and communication.
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Irish legislation recognises the need to consider the cost-effectiveness of health 
services, both for new interventions and their opportunity cost. Ireland did not 
have an explicit cost-effectiveness threshold until a 2012 agreement between the 
pharmaceutical industry and government established a € 45,000/QALY threshold. 
It was agreed as part of a deal that provided cost savings on existing medications 
and only applies to pharmaceuticals: there is no official threshold for non-drug 
interventions. Drugs with cost-effectiveness ratios within the threshold are guar-
anteed reimbursement, whereas those exceeding the threshold may be approved 
following further negotiation. A number of drugs far exceeding the threshold have 
been reimbursed in Ireland in recent years. There are four reasons for concern 
regarding Ireland’s threshold. Firstly, as a price floor not a ceiling it offers only a 
weak constraint on the introduction of cost-ineffective interventions, which leaves 
little scope for positive net health benefit. Secondly, that the threshold only applies 
to drugs creates potential for inconsistencies whereby relatively cost-effective 
non-drug interventions may not necessarily be approved, leading to sub-opti-
mal resource allocation. Thirdly, the current threshold has no apparent empiri-
cal basis. Finally, recent efforts to determine the appropriate cost-effectiveness 
threshold in the UK have estimated a threshold of approximately £13,000/QALY. 
Assuming Ireland’s threshold should be broadly comparable, the current Irish 
threshold is most probably too high. Consequently, reimbursing new interven-
tions at and above the € 45,000/QALY threshold is likely to result in net harm, as 
new drugs produce less health than the interventions they displace. The failure 
of Ireland’s threshold to be empirically determined by the cost-effectiveness of 
services foregone means the requirements of current legislation are not being 
met and reimbursement decisions cannot be considered fully evidenced-based. 
It is likely the current threshold is excessive and will lead to systematic damage 
of the health system.
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bAckgROund: Observational studies have been one of the hallmarks for the devel-
opment of public health and health economics fields. It includes epidemiologic stud-
ies, evaluation of patterns of care, use of resources, cost of illness, analysis of safety 
and effectiveness of interventions from real world. However, there are different pat-
terns of requirements for ethics reviews concerning observational studies, including 
vastly available models of ethics systems among different countries. Therefore, 
the objective of this study is to evaluate the ethics system, regulations and guide-
lines concerning observational studies in the selected countries. MethOdOlOgy: 
Guidelines and regulations from Brazil, Argentina, Japan, New Zealand, Australia, 
USA and UK were reviewed to evaluate the ethics system and available guiding 
principle for observational studies. Additionally, a literature review was performed 
in the database Medline and SciELO mesh using the terms “ethics”, “observational 
study” and “multicenter study” among other similar terms. Results: In Brazil, 
same ethics regulation is applied for both interventional and observational projects, 
plus there is unsatisfactory ethics review timelines and duplicity of ethics review 
when considering multicenter studies. Specific pathways for multicenter studies 
are available only in New Zealand, Australia, USA and UK. For the exception of Brazil, 
other evaluated countries have specific guidelines, recommendations or regulations 
for observational studies. cOnclusiOns: Brazil and Argentina still have a lot of 
and governmental authorities, case studies and the latest publications in value-based 
assessment (VBA) was performed to summarise the current perception of RWD, and 
to identify the advantages and challenges of using RWD to support market access and 
reimbursement. Only 10 guidelines were found from 73 European HTA agencies or 
governmental authorities which cited RWD as a source for evidence. NICE acknowl-
edges the difficulties of generalising RCT results to clinical practice, and supports 
the capture and analysis of observational data. In addition, recent developments in 
VBA anticipate a greater scrutiny of attempts to model natural history in economic 
evaluations, which may be addressed by using longitudinal observational data. Case 
studies have shown economic evaluations based on RCT data may lack external 
validity, and may consequently produce inaccurate estimates of economic endpoints. 
There is a consensus that RWD are valuable in providing clinical practice evidence on 
treatment pathways, resource use, long-term natural history and true effectiveness. 
However, there are methodological challenges (such as lack of randomisation) to 
be addressed before RWD are widely accepted as a complement to RCTs to support 
decision-making. RWD are increasingly recognised as a valuable source of evidence 
for market access and reimbursement, and as a complement to clinical trial evidence. 
Nevertheless, there are challenges that need to be addressed to ensure real world data 
provide valid evidence to the decision process.
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Combinations of high-cost branded drugs are becoming a reality. The synergistic 
value of combining two potent drugs is expected to considerably bolster the benefit 
to the patient in terms of efficacy and, in some cases, even safety. However, the syn-
ergistic cost of using branded combinations increases exponentially due to longer 
treatment durations, thus making the total treatment cost unaffordable to European 
health systems. This poster aims to explore the pricing and reimbursement issues 
that health systems will encounter during the evaluation of branded combination 
therapies and potential solutions to make these combinations affordable by the 
health care systems and ensure patient access to innovative drugs. To meet these 
objectives, an in-depth review of published sources was conducted, including a 
thorough analogue assessment. Moreover, targeted interviews with twenty payers 
involved at different levels of pricing and market access decision-making in the 
EU5 were also conducted to support analysis. Research revealed that synergistic 
costs of already expensive monotherapies, further exacerbated by longer duration 
of treatment, exceed payers’ cost thresholds. Therefore, on one hand payers will 
struggle to award a value-based price for the individual drugs as well as for the 
combination and will look to discount and/or restrict access. On the other hand, as 
this approach will not reflect the combination’s synergistic value and could threaten 
the life-cycle indications of each compound, manufacturers may not launch in some 
markets, thus, limiting patient access. Consequently, it is important to find a balance 
in setting a value-based price for individual indications and for the combinations 
to ensure broad patient access. Aligning patient, payer and manufacturer needs is 
paramount to find a win-win-win solution. In the context of brand-on-brand combi-
nations, traditional pricing models are not the solution and alternative approaches 
need to be adopted.
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bAckgROund: Knowledge of payer evidence requirements is vital to manufac-
turers who are facing increasing development costs for uncertain market access 
outcomes. Failure to engage payers early in asset development could result in delay 
of approval and/or coverage. Objectives: Build the case for early payer engage-
ment as a means of reconciling the needs of payers and manufacturers MethOds: 
A literature search was performed and primary research with key opinion leaders 
in the US and EU was conducted to characterize 5 early engagement strategies 
(informal consultation, formal consultation, outcomes-based risk sharing, financial-
based risk sharing, and formal partnerships). 7 major markets (Canada, France, 
Italy, Germany, Spain, UK, and US) were also assessed for their historic use of early 
engagement models. Results: Payers want more manufacturer involvement in evi-
dence development, including input into clinical trial design and RWE development 
in phases II and III through formal and informal consultations. Articulation of an 
asset’s value story in the peri-launch phase and negotiations with regional and local 
payers through direct consultations allows manufacturers to position the asset for 
optimal pricing and reimbursement. When agreement cannot be reached on price 
or reimbursement terms, risk-sharing agreements allow broader access in exchange 
for the manufacturer bearing incrementally greater financial risk. Manufacturers 
have also built partnerships to uncover the real-world value of therapies and gain 
insight into usage and adherence patterns. Each market has its own challenges 
for promoting collaboration, requiring manufacturers to tailor their approach to 
the various national and local payers cOnclusiOn: Early planning is imperative 
in value-focused health care. When early payer engagement succeeds, it provides 
manufacturers time to design informed strategies to meet payer valuation needs. 
Evidence development that is closely aligned with payer requirements results in 
therapies that are more cost effective and gain quicker market access, benefitting 
manufacturers, payers, and patients alike.
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